Unresectable Hepatocellular Carcinoma

• FDA approval · 2026-02-03
  FDA Approved: STIVARGA — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

  The FDA approved a supplemental application for STIVARGA (regorafenib) to expand its indications.

• CLINICAL_TRIALS trial_result · 2023-11-08
  Clinical Trial Update: Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer [NA]

  Trial results for TheraSphere in patients with unresectable hepatocellular carcinoma have been completed with results posted.

• CLINICAL_TRIALS trial_result · 2023-02-17
  Clinical Trial Update: Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery [Phase 3]

  Phase 3 clinical trial evaluating chemoembolization with or without sorafenib for unresectable hepatocellular carcinoma has completed.

• CLINICAL_TRIALS trial_result · 2022-10-17
  Clinical Trial Update: HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC [Phase 2]

  Phase 2 trial comparing HAIC+Lenvatinib+Tislelizumab to D-TACE+Lenvatinib+Tislelizumab for unresectable hepatocellular carcinoma is ongoing …

• FDA approval · 2020-07-21
  FDA Approved: STIVARGA — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

  FDA approved a supplemental application for Stivarga (regorafenib) from Bayer, expanding its approved uses.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2018-06-06
  FDA Approved: LENVIMA — Supplemental Application (Eisai Inc.)

  FDA approved a supplemental application for LENVIMA (lenvatinib) submitted by Eisai Inc.

• CLINICAL_TRIALS trial_result · 2013-02-26
  Clinical Trial Update: Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer [Phase 1]

  Phase 1 study assessing the safety of combining sorafenib tosylate with chemoembolization in patients with unresectable hepatocellular carci…